Cargando…

Eribulin sensitizes oral squamous cell carcinoma cells to cetuximab via induction of mesenchymal-to-epithelial transition

Inhibition of epidermal growth factor receptor (EGFR) signalling has emerged as a new treatment strategy for oral squamous cell carcinoma (OSCC). Previously, we found that loss of EGFR expression in OSCC was associated with epithelial-mesenchymal transition (EMT), and may have functional implication...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kitahara, Hiroko, Hirai, Mariko, Kato, Koroku, Bou-Gharios, George, Nakamura, Hiroyuki, Kawashiri, Shuichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2016
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5112623/ https://www.ncbi.nlm.nih.gov/pubmed/27779690 http://dx.doi.org/10.3892/or.2016.5189

Ejemplares similares

Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment
por: Hirai, Mariko, et al.
Publicado: (2016)

Selectively high efficacy of eribulin against high-grade invasive recurrent and/or metastatic squamous cell carcinoma of the head and neck
por: Kobayashi, Yutaka, et al.
Publicado: (2019)

Clinicopathological Significance of the ET Axis in Human Oral Squamous Cell Carcinoma
por: Miyazawa, Hiroki, et al.
Publicado: (2018)

Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage
por: Hira-Miyazawa, Mayuko, et al.
Publicado: (2017)

Loss of epidermal growth factor receptor expression in oral squamous cell carcinoma is associated with invasiveness and epithelial-mesenchymal transition
por: KIMURA, IYO, et al.
Publicado: (2016)

Tumour: Fibroblast Interactions Promote Invadopodia-Mediated Migration and Invasion in Oral Squamous Cell Carcinoma
por: Kato, Koroku, et al.
Publicado: (2022)

The pattern and spread of invasion can predict late cervical lymph node metastasis in early tongue squamous cell carcinoma
por: Kato, Koroku, et al.
Publicado: (2023)

Metalloelastase-12 is involved in the temporomandibular joint inflammatory response as well as cartilage degradation by aggrecanases in STR/Ort mice
por: Yamashita-Futani, Yoko, et al.
Publicado: (2021)

Induction chemotherapy with cetuximab, carboplatin and paclitaxel for the treatment of locally advanced squamous cell carcinoma of the head and neck
por: BAUMAN, JESSICA, et al.
Publicado: (2013)

Feasibility of Induction Docetaxel, Cisplatin, 5-Fluorouracil, Cetuximab (TPF-C) Followed by Concurrent Cetuximab Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Charalambakis, Nikolaos, et al.
Publicado: (2013)

Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck
por: Merlano, Marco, et al.
Publicado: (2007)

Cost-Effectiveness of Cetuximab for Advanced Esophageal Squamous Cell Carcinoma
por: Janmaat, Vincent T., et al.
Publicado: (2016)

Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma
por: Marin-Acevedo, Julian A., et al.
Publicado: (2023)

Eribulin inhibits growth of cutaneous squamous cell carcinoma cell lines and a novel patient-derived xenograft
por: Hsu, Che-Yuan, et al.
Publicado: (2023)

Development of interstitial pneumonia during treatment with eribulin: a case report
por: Nakamura, Kota, et al.
Publicado: (2017)

Eribulin Mesylate Targets Human Telomerase Reverse Transcriptase in Ovarian Cancer Cells
por: Yamaguchi, Satoko, et al.
Publicado: (2014)

Eribulin drug review
por: Shetty, Nishitha, et al.
Publicado: (2014)

Eribulin in Cancer Treatment
por: Swami, Umang, et al.
Publicado: (2015)

Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
por: Ho, Gwo Yaw, et al.
Publicado: (2022)

Cetuximab Rechallenge and Monotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck
por: Knutzen, Greg, et al.
Publicado: (2015)

Clinical Remission of Cutaneous Squamous Cell Carcinoma of the Auricle with Cetuximab and Nivolumab
por: Chen, Alessandra, et al.
Publicado: (2018)

Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma
por: Leblanc, Olivia, et al.
Publicado: (2020)

Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states
por: Yoshida, T, et al.
Publicado: (2014)

Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status
por: Baysal, Hasan, et al.
Publicado: (2020)

Tomotherapy concomitant with cetuximab, followed by cetuximab as single-agent therapy for unresectable squamous cell carcinoma of the skin: a case report
por: Falivene, Sara, et al.
Publicado: (2014)

In vitro radiosensitization by eribulin in human cancer cell lines
por: Benlloch, Raquel, et al.
Publicado: (2022)

Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy
por: Marín-Jiménez, Juan A., et al.
Publicado: (2022)

Combination of eribulin plus AKT inhibitor evokes synergistic cytotoxicity in soft tissue sarcoma cells
por: Hayasaka, Naotaka, et al.
Publicado: (2019)

Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck
por: Perri, Francesco, et al.
Publicado: (2009)

Efficacy of gemcitabine and cetuximab combination treatment in head and neck squamous cell carcinoma
por: MASEKI, SHINICHIRO, et al.
Publicado: (2013)

In Vivo Fluorescence Immunohistochemistry: Localization of Fluorescently Labeled Cetuximab in Squamous Cell Carcinomas
por: de Boer, Esther, et al.
Publicado: (2015)

Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment
por: Galbiati, Donata, et al.
Publicado: (2019)

Dramatic response of refractory metastatic squamous cell carcinoma of the skin with cetuximab/pembrolizumab
por: Hober, Candice, et al.
Publicado: (2021)

Gene Expression Profiling Reveals Epithelial Mesenchymal Transition (EMT) Genes Can Selectively Differentiate Eribulin Sensitive Breast Cancer Cells
por: Dezső, Zoltán, et al.
Publicado: (2014)

Effects of Cetuximab and Erlotinib on the behaviour of cancer stem cells in head and neck squamous cell carcinoma
por: Setúbal Destro Rodrigues, Maria Fernanda, et al.
Publicado: (2018)

Stathmin dynamics modulate the activity of eribulin in breast cancer cells
por: Yoshie, Mikihiro, et al.
Publicado: (2021)

Aggrecanase-selective tissue inhibitor of metalloproteinase-3 (TIMP3) protects articular cartilage in a surgical mouse model of osteoarthritis
por: Nakamura, Hiroyuki, et al.
Publicado: (2020)

Silencing Smad4 attenuates sensitivity of colorectal cancer cells to cetuximab by promoting epithelial-mesenchymal transition
por: Lin, Zhenlv, et al.
Publicado: (2019)

JunB mediates enhancer/promoter activity of COL1A2 following TGF-β induction
por: Ponticos, Markella, et al.
Publicado: (2009)

Aurora Kinase Inhibition Overcomes Cetuximab Resistance in Squamous Cell Cancer of the Head and Neck
por: Hoellein, Alexander, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_3lisfd1as0t9672qu97jll7jm9